Evidence map›Paper›PMID 39088067›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2024

The association of quantitative PSMA PET parameters with pathologic ISUP grade: an international multicenter analysis.

Timo F W Soeterik, Joris G Heetman, Rick Hermsen, Lieke Wever, Jules Lavalaye, Maarten Vinken, Clinton D Bahler, Courtney Yong, Mark Tann, Claudia Kesch and 17 more

Abstract readMulticenter Study
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Predictive value of theAnnals of nuclear medicine · 2026
    Article
  5. Review
  6. Article
  7. Article
  8. The predictive value of multiparametric MRI combined with [European journal of nuclear medicine and molecular imaging · 2025
    Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Timo F W SoeterikDepartment of Urology, St. Antonius Hospital, Koekoekslaan 1, 3435 CM, Nieuwegein, The Netherlands. timo142@gmail.com.ORCID http://orcid.org/0000-0002-0259-8750
Joris G HeetmanDepartment of Urology, St. Antonius Hospital, Koekoekslaan 1, 3435 CM, Nieuwegein, The Netherlands.
Rick HermsenDepartment of Nuclear Medicine, Canisius Wilhelmina Hospital, Nijmegen, The Netherlands.
Lieke WeverDepartment of Urology, St. Antonius Hospital, Koekoekslaan 1, 3435 CM, Nieuwegein, The Netherlands.
Jules LavalayeDepartment of Nuclear Medicine, St. Antonius Hospital, Nieuwegein/Utrecht, The Netherlands.
Maarten VinkenDepartment of Nuclear Medicine, Canisius Wilhelmina Hospital, Nijmegen, The Netherlands.
Clinton D BahlerDepartment of Urology, Indiana University Medical Center, Indianapolis, IN, USA.
Courtney YongDepartment of Urology, Indiana University Medical Center, Indianapolis, IN, USA.
Mark TannDepartment of Radiology and Imaging Sciences, Indiana University Medical Center, Indianapolis, IN, USA.
Claudia KeschDepartment of Urology, University Hospital Essen, Essen German Cancer Consortium (DKTK) University Hospital Essen, Essen, Germany.
Robert SeifertDepartment of Nuclear Medicine, Inselspital, Bern University Hospital, Bern, Switzerland.
Tugce TelliDepartment of Nuclear Medicine, University Hospital Essen, Essen, Germany.
Peter Ka-Fung ChiuS. H. Ho Urology Centre, Department of Surgery, The Chinese University of Hong Kong, Hong Kong, China.
Kwan Kit WuDepartment of Nuclear Medicine and PET, Hong Kong Sanatorium and Hospital, Hong Kong, China.
Fabio ZattoniDepartment of Surgery, Oncology, and Gastroenterology, Urological Unit, University of Padova, Padua, Italy.
Laura EvangelistaDepartment of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.
Emma SegallaDepartment of Surgery, Oncology, and Gastroenterology, Urological Unit, University of Padova, Padua, Italy.
Antonio BaroneDivision of Nuclear Medicine and Theranostics, IEO European Institute of Oncology, IRCCS, Milan, Italy.
Francesco CeciDivision of Nuclear Medicine and Theranostics, IEO European Institute of Oncology, IRCCS, Milan, Italy.
Pawel RajwaDepartment of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
Giancarlo MarraUniversity Hospital S Giovanni Battista, Azienda Ospedaliero Universitaria Città Della Salute E Della Scienza Di Torino, Turin, Italy.
Elio MazzoneDivision of Oncology/Unit of Urology, Soldera Prostate Cancer Lab, URI, IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy.
Jean-Paul A Van BastenDepartment of Urology, Canisius Wilhelmina Hospital, Nijmegen, The Netherlands.
Harm H E Van MelickDepartment of Urology, St. Antonius Hospital, Koekoekslaan 1, 3435 CM, Nieuwegein, The Netherlands.
Roderick C N Van den BerghDepartment of Urology, St. Antonius Hospital, Koekoekslaan 1, 3435 CM, Nieuwegein, The Netherlands.
Giorgio GandagliaDivision of Oncology/Unit of Urology, Soldera Prostate Cancer Lab, URI, IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy.
EAU-YAU Prostate Cancer Working Party

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo assess if PSMA PET quantitative parameters are associated with pathologic ISUP grade group (GG) and upgrading/downgrading.

methodsPCa patients undergoing radical prostatectomy with or without pelvic lymph node dissection staged with preoperative PSMA PET at seven referral centres worldwide were evaluated. PSMA PET parameters which included SUV

resultsA total of 605 patients were included. Overall, 2%, 37%, 37%, 10% and 13% patients had pathologic ISUP GG1, 2, 3, 4, and 5, respectively. At multivariable analyses, all three parameters SUV

conclusionQuantitative PSMA PET parameters are associated with surgical ISUP GG and upgrading. We propose clinically relevant thresholds of these parameters which can improve in PCa risk stratification in daily clinical practice.

Indexed as

Glutamate Carboxypeptidase IIProstatic NeoplasmsAgedAntigens, SurfaceHumansMaleMiddle AgedNeoplasm GradingPositron-Emission TomographyProstatectomyAntigens, SurfaceFOLH1 protein, humanGlutamate Carboxypeptidase IIHistologyISUP grade groupProstate cancerPSMA PET/CT

Identifiers

PMID39088067
PMCPMC11599533

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.